Free Trial

Panbela Therapeutics (PBLA) Competitors

Panbela Therapeutics logo
$0.16 +0.00 (+1.91%)
As of 12:09 PM Eastern

PBLA vs. SNOA, GLTO, LIPO, MTNB, MBIO, RDHL, SNGX, INM, CNSP, and TTNP

Should you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Sonoma Pharmaceuticals (SNOA), Galecto (GLTO), Lipella Pharmaceuticals (LIPO), Matinas Biopharma (MTNB), Mustang Bio (MBIO), Redhill Biopharma (RDHL), Soligenix (SNGX), InMed Pharmaceuticals (INM), CNS Pharmaceuticals (CNSP), and Titan Pharmaceuticals (TTNP). These companies are all part of the "pharmaceutical products" industry.

Panbela Therapeutics vs. Its Competitors

Panbela Therapeutics (NASDAQ:PBLA) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Panbela Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Sonoma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Panbela Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Panbela Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -24.23%. Panbela Therapeutics' return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Panbela TherapeuticsN/A N/A -302.61%
Sonoma Pharmaceuticals -24.23%-58.73%-21.05%

In the previous week, Panbela Therapeutics' average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Panbela Therapeutics Neutral
Sonoma Pharmaceuticals Neutral

4.4% of Panbela Therapeutics shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 0.0% of Panbela Therapeutics shares are held by company insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sonoma Pharmaceuticals has higher revenue and earnings than Panbela Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Panbela TherapeuticsN/AN/A-$25.26M-$71.130.00
Sonoma Pharmaceuticals$14.29M0.34-$3.46M-$3.10-0.96

Summary

Panbela Therapeutics beats Sonoma Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Panbela Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PBLA vs. The Competition

MetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$777K$783.59M$5.49B$9.01B
Dividend YieldN/A4.84%5.39%4.11%
P/E Ratio0.001.3127.4320.06
Price / SalesN/A222.00398.97108.32
Price / CashN/A23.4436.1356.90
Price / Book-0.016.108.085.67
Net Income-$25.26M-$27.81M$3.16B$248.47M
7 Day Performance-23.81%0.68%2.12%2.90%
1 Month Performance-46.67%7.16%4.43%5.75%
1 Year Performance-55.81%7.89%35.62%21.36%

Panbela Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PBLA
Panbela Therapeutics
0.0867 of 5 stars
$0.16
+1.9%
N/A-56.6%$777KN/A0.006
SNOA
Sonoma Pharmaceuticals
N/A$2.93
-0.3%
N/A+1,143.6%$4.81M$14.29M-0.95180Positive News
GLTO
Galecto
3.4039 of 5 stars
$3.50
+3.9%
$10.00
+185.7%
-69.8%$4.63MN/A-0.2340Negative News
Gap Down
LIPO
Lipella Pharmaceuticals
1.3757 of 5 stars
$1.02
-7.3%
N/A-77.4%$4.56M$540K-0.254
MTNB
Matinas Biopharma
0.1629 of 5 stars
$0.90
+1.7%
N/AN/A$4.55M$1.10M-0.1830Positive News
MBIO
Mustang Bio
1.0278 of 5 stars
$1.04
+0.5%
N/A-95.6%$4.53MN/A-0.01100News Coverage
RDHL
Redhill Biopharma
N/A$1.92
+1.3%
N/A-99.1%$4.39M$8.04M0.00210News Coverage
SNGX
Soligenix
0.9167 of 5 stars
$1.36
-17.6%
N/A-44.5%$4.39M$120K-0.3120News Coverage
Gap Down
High Trading Volume
INM
InMed Pharmaceuticals
1.0401 of 5 stars
$3.58
+45.9%
N/A-38.9%$4.29M$4.92M-0.2910Gap Up
High Trading Volume
CNSP
CNS Pharmaceuticals
1.5416 of 5 stars
$0.76
+0.1%
$25.00
+3,189.5%
-98.5%$4.15MN/A0.005
TTNP
Titan Pharmaceuticals
0.3341 of 5 stars
$4.52
+6.1%
N/A-18.0%$4.11M$180K-0.9810

Related Companies and Tools


This page (NASDAQ:PBLA) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners